Nektar Therapeutics (NKTR) Expected to Announce Earnings on Monday

Nektar Therapeutics (NASDAQ:NKTR) is projected to announce its earnings results before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $36.65 million for the quarter.

Nektar Therapeutics Stock Up 5.9 %

NKTR opened at $0.84 on Friday. The stock’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $1.11. The firm has a market capitalization of $155.50 million, a P/E ratio of -1.00 and a beta of 0.58. Nektar Therapeutics has a 12-month low of $0.65 and a 12-month high of $1.93.

Insider Transactions at Nektar Therapeutics

In other Nektar Therapeutics news, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the sale, the insider now directly owns 351,892 shares in the company, valued at $316,702.80. This represents a 8.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the sale, the insider now owns 326,904 shares in the company, valued at $307,289.76. This represents a 13.52 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 165,586 shares of company stock valued at $159,990. Company insiders own 3.71% of the company’s stock.

Analysts Set New Price Targets

NKTR has been the topic of several research analyst reports. B. Riley started coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a report on Tuesday. Piper Sandler began coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective for the company. Finally, William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a research report on Tuesday. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $4.08.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.